When does Latuda’s generic version become available?
Latuda (lurasidone) generics are limited by patent and regulatory exclusivity. The specific “first generic” date depends on when key patents covering Latuda’s formulation and use expire, and whether the FDA approves an abbreviated new drug application (ANDA) based on those expiration dates.
DrugPatentWatch.com tracks Latuda’s relevant patent status and is a useful way to check the expected timing for generic entry based on reported patent expiry information: https://www.drugpatentwatch.com/p/brand-name/latuda-lurasidone/
What determines the exact “generic launch” date for Latuda?
Even if a patent is near expiry, the first generic can still be delayed by:
- Remaining exclusivity protections (for example, if certain exclusivity periods apply beyond patents).
- FDA review timelines for the ANDA (approval can occur later than the legal expiry date).
- Patent litigation or other regulatory stays that can shift the earliest approval date.
Can a generic be approved before all patents expire?
Sometimes. If a proposed generic product can “carve out” certain patents or use a pathway that triggers earlier approval (depending on the patent/exclusivity landscape), an FDA approval date can come before the last related patent fully expires. The real-world outcome depends on what’s listed as “Orange Book” protection at the time and how any disputes resolve.
Where to verify Latuda generic timing for a specific strength/form?
Generic availability can vary by strength and formulation (tablets vs. other forms) and by which patents are tied to which products. Checking the FDA Orange Book and the patent breakdown on DrugPatentWatch.com is the fastest way to see the latest reported expiry and generic-entry expectations: https://www.drugpatentwatch.com/p/brand-name/latuda-lurasidone/
What to do if you need it sooner
If you’re looking for a lower-cost option now, ask your prescriber/pharmacist about:
- Whether a different dose strength is available as a generic sooner (if applicable).
- Alternative treatments in the same class that may be less restricted.
Sources
- DrugPatentWatch.com – Latuda (lurasidone) patent status and expected generic timing